OTLK · Outlook Therapeutics, Inc. · Debt
$0.52
-0.04 (-7.84%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because our cash and cash equivalents, together with $51.1 million of net proceeds from our August 2026 Offering, will not be adequate to fund our currently planned operations through at least the 12 months from the date of this Quarterly Report, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 18, 2026
Market Cap
$126.42M
Shares
243.45M
Volume · Oct 23
3.08M
Avg daily vol (3M)
12.5M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of unsecured debt | 2026-06-30 | USD 18,227,000 | 10-Q filed 2026-08-18 |
| Operating lease liabilities | 2026-06-30 | USD 204,144 | 10-Q filed 2026-08-18 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1649989
CUSIP
69012T305
13F (30d)
16 filings
12 filers
Visit website
Investor relations